Voyager Therapeutics (VYGR) EBITDA (2014 - 2026)

Voyager Therapeutics has disclosed EBITDA across 13 years of filings, most recently posting -$28.2 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$28.2 million, up 8.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$116.7 million (down 38.29% YoY), and the FY2025 annual result was -$119.3 million, down 82.5% from the prior year.
• EBITDA came in at -$28.2 million for Q1 2026 at Voyager Therapeutics, down from -$27.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $124.1 million in Q1 2023 to a low of -$34.9 million in Q4 2024.
• The 5-year median for EBITDA is -$22.2 million (2023), against an average of -$7.5 million.
• Across the five-year window, EBITDA plunged 512.49% in 2022 and soared 679.94% in 2023, its largest moves.
• Voyager Therapeutics' EBITDA stood at -$23.5 million in 2022, then jumped by 340.75% to $56.6 million in 2023, then tumbled by 161.6% to -$34.9 million in 2024, then gained by 21.4% to -$27.4 million in 2025, then fell by 3.03% to -$28.2 million in 2026.
• The last three EBITDA figures came in at -$28.2 million (Q1 2026), -$27.4 million (Q4 2025), and -$27.7 million (Q3 2025), per Business Quant data.